Biocon Expands Into Middle East With Tabuk Partnership
Tabuk Will Commercialize Select Biocon Generics In The Region
Biocon is set to bolster its planned expansion into the MENA region through a partnership with Saudi firm Tabuk Pharmaceuticals, which will commercialize select Biocon generics in the Middle East.
You may also be interested in...
Having together achieved success with biosimilar trastuzumab in Brazil, Biocon and local player Libbs Farmaceutica have reached an agreement to offer the Indian firm’s generic formulations in the market.
Indian company Biocon is aiming to “deliver substantial savings to healthcare systems” by enhancing access to and availability of oncology biosimilars in 25 countries in Africa and five countries in Asia, covered under the Cancer Access Partnership, led by the Clinton Health Access Initiative.
Lupin has announced a number of drug approvals in the US, as well as a biosimilar partnership in the Middle East and the launch of a novel fixed-dose triple combination drug in its native Indian market.